Eximis Surgical Inc.

Eximis Surgical Inc. is a medical technology company focused on developing innovative solutions for minimally invasive surgery, particularly through their flagship device for efficient specimen removal. Founded in 2014 in Louisville, US, Eximis Surgical Inc. specializes in advanced surgical technologies.

The company has received venture funding led by Questa Capital Management, raising a total of USD 7. 50 mn. Kristin Johnson and William Gregg founded the company, with Kristin Johnson currently serving as CEO. The latest funding round occurred on November 8, 2018, and targeted the company's efforts to enhance its product offerings and market reach.

Eximis Surgical specializes in the development of innovative solutions for minimally invasive surgery (MIS), focusing on their flagship device designed for safe and efficient specimen removal. This device addresses the common issue of larger incision sizes, which can extend up to 7cm, even when utilizing advanced surgical robotics for procedures that begin with pencil-sized incisions. By maintaining smaller incisions throughout the surgical process, Eximis Surgical aims to provide approximately 2 million patients with reduced postoperative pain, shorter hospital stays, and quicker recovery times. The company serves healthcare facilities and surgical centers in North America and Europe, targeting gynecologic oncologists and other specialists engaged in intra-abdominal surgeries, positioning itself as a critical player in the evolving landscape of minimally invasive surgical technologies.

Eximis Surgical’s revenue model centers around direct sales to healthcare providers, including hospitals and outpatient surgical centers, utilizing their innovative surgical devices. Transactions typically involve the purchase of their proprietary specimen removal device, designed to streamline surgical procedures while improving patient outcomes. The company engages in educational partnerships and training programs to support the adoption of their technology among medical professionals, fostering collaboration for enhanced surgical practices. Pricing plans are tailored to institutional clients, considering factors like purchase volume and service contracts, optimizing integration into surgical offerings across key markets.

Eximis Surgical plans to utilize the USD 7. 50 mn raised in its most recent funding round to support the development of new products aimed at enhancing minimally invasive surgical techniques. The company is also targeting expansion into additional markets across North America and Europe to increase its reach among healthcare providers. As the company moves forward, it will focus on refining its existing products and supporting the launch of new innovations to improve surgical outcomes, with indications of further advancements projected for the near future.